Condition
Peanut-Induced Anaphylaxis
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07349212Phase 1RecruitingPrimary
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
NCT05621317Phase 2Active Not Recruiting
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
NCT05695261Phase 2Recruiting
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Showing all 3 trials